Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).